Summit Therapeutics Inc (SMMT)

Oct 03, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire

Oct 03, 2025

Oct 03, 2025

How to use Fibonacci retracement on Summit Therapeutics Inc.Take Profit & Daily Profit Focused Stock Screening - newser.com

Oct 03, 2025

Oct 03, 2025

How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st

Oct 03, 2025

Oct 03, 2025

How to monitor Summit Therapeutics Inc. with trend dashboards2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com

Oct 03, 2025

Oct 03, 2025

Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com

Oct 03, 2025

Oct 03, 2025

Is Summit Therapeutics Inc. stock supported by strong cash flowsRisk Management & Safe Entry Zone Identification - newser.com

Oct 03, 2025

Oct 02, 2025

A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance

Oct 02, 2025

Oct 02, 2025

H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN

Oct 02, 2025

Oct 01, 2025

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga

Oct 01, 2025

Oct 01, 2025

Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo Finance

Oct 01, 2025

Oct 01, 2025

Will Summit Therapeutics Inc. stock continue dividend increasesJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com

Oct 01, 2025

Sep 30, 2025

Published on: 2025-09-30 03:00:28 - newser.com

Sep 30, 2025

Sep 30, 2025

Published on: 2025-09-30 00:09:58 - newser.com

Sep 30, 2025

Sep 29, 2025

Will Summit Therapeutics Inc. stock gain from lower inflationWeekly Profit Recap & Pattern Based Trade Signal System - newser.com

Sep 29, 2025

Sep 29, 2025

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN

Sep 29, 2025

Sep 29, 2025

What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in

Sep 29, 2025

Sep 27, 2025

Summit Therapeutics Inc Stock Analysis and ForecastAI-Driven Market Analysis & Learn From the Strategies of Institutions - earlytimes.in

Sep 27, 2025

Sep 25, 2025

Positive Catalyst Watch Boosts SMMT Stock Outlook - GuruFocus

Sep 25, 2025

Sep 25, 2025

Barclays Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛

Sep 25, 2025

Sep 24, 2025

Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener

Sep 24, 2025

Sep 24, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent

Sep 24, 2025

Sep 24, 2025

First-Ever PD-1 Therapy Superiority: Summit's Ivonescimab Achieves Breakthrough in Advanced Lung Cancer Trial - Stock Titan

Sep 24, 2025

Sep 24, 2025

Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT) - Defense World

Sep 24, 2025

Sep 23, 2025

Voya Investment Management LLC Sells 34,041 Shares of Summit Therapeutics PLC $SMMT - MarketBeat

Sep 23, 2025

Sep 23, 2025

Summit Therapeutics PLC $SMMT Shares Sold by Wealth Management Partners LLC - MarketBeat

Sep 23, 2025

Sep 22, 2025

Barclays Begins Coverage on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat

Sep 22, 2025

Sep 22, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire

Sep 22, 2025

Sep 22, 2025

Summit Therapeutics Inc. stock chart pattern explainedWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com

Sep 22, 2025

Sep 22, 2025

Summit Therapeutics Inc. (SMMT) Stock Analysis: Assessing a 73% Potential Upside Amidst Clinical Innovations - DirectorsTalk Interviews

Sep 22, 2025

Sep 21, 2025

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat

Sep 21, 2025

Sep 21, 2025

Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - MSN

Sep 21, 2025

Sep 20, 2025

Will Summit Therapeutics Inc. benefit from macro trendsJuly 2025 Fed Impact & High Conviction Investment Ideas - newser.com

Sep 20, 2025

Sep 20, 2025

Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright - MarketBeat

Sep 20, 2025

Sep 20, 2025

Aug Catalysts: Is Summit Therapeutics Inc benefiting from innovation trendsTrade Entry Summary & Reliable Price Breakout Signals - خودرو بانک

Sep 20, 2025

Sep 20, 2025

Breakout Watch: Is Summit Therapeutics Inc vulnerable to short sellersJuly 2025 Review & Fast Gain Stock Trading Tips - خودرو بانک

Sep 20, 2025

Sep 20, 2025

Voya Investment Management LLC Lowers Stock Position in Summit Therapeutics PLC $SMMT - Defense World

Sep 20, 2025

Sep 20, 2025

Is a relief rally coming for Summit Therapeutics Inc. holdersMarket Sentiment Report & Community Trade Idea Sharing Platform - newser.com

Sep 20, 2025

Sep 19, 2025

Real time alert setup for Summit Therapeutics Inc. performanceStop Loss & Stepwise Trade Signal Implementation - newser.com

Sep 19, 2025

Sep 19, 2025

Institution Moves: Is CMND stock heavily shorted2025 Earnings Surprises & Consistent Return Investment Signals - khodrobank.com

Sep 19, 2025